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Evidence is lacking that oversight by pharmacists has benefits, writes Paul Rutter, who 
thinks that the US dichotomy of prescription-only and non-prescription drugs is simpler 
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In January 2015 the UK Medicines and Healthcare Products Regulatory Agency 
announced that oral diclofenac would no longer be available as a non-prescription drug sold 
exclusively under the direction of a pharmacist (a “pharmacy medicine”). Instead, it would 
revert to prescription-only control because of a small but notably increased risk of 
cardiovascular side effects.[1] 
Despite oral diclofenac having previously been restricted to sale through pharmacies the 
UK regulator decided that risks could not be ruled out—even in short term use and at lower 
doses than those prescribed. This implies that, even with this system of restricted availability, 
doubt exists that pharmacists (and their staff) can supervise sales to consumers appropriately. 
Given this decision, should any drugs still be restricted to sale only with a pharmacist’s 
supervision? Globally, many governments have healthcare policies that advocate for less 
prescription-only control of drugs. The mechanism for deregulation varies, but consumers 
worldwide can access drugs more easily than ever before.[2] Use of non-prescription drugs is 
the most prevalent form of medical care in the world, with a global market worth an 
estimated €73bn (£52bn; $82bn), and their sales growth now exceeds that of prescription-
only drugs.[3] 
Many countries (including Australia, Canada, France, New Zealand, Sweden, and the 
United Kingdom) foster the declassification of drugs that are under prescription-only control 
by having a category of drugs that can be bought only at a pharmacy. These “pharmacy 
medicines” must be sold either by pharmacists or under their supervision. In the past 30 years 
this approach to reclassification has seen many therapeutic agents made available to 
consumers without a prescription, including proton pump inhibitors (in the United States and 
the European Union), orlistat (EU), triptans (UK and Germany), and β2 agonists (Singapore 
and Australia). 
Helping patients care for themselves 
Some may argue that the “pharmacy medicines” category helps pharmacists in the 
community to help patients care for themselves[4] and that the more drugs become available 
this way, the more opportunity this gives pharmacists to reduce people’s need to access 
general medical services, thereby reducing doctors’ workloads.[5] 
These arguments have been used by government and pharmacy organisations to champion 
a bigger role for community pharmacists. This may seem sensible and appropriate; 
pharmacies manage large numbers of consumers who seek advice and help for many minor 
illnesses.[2] [65] But does their 4-6 years of drug training mean that they should have a 
monopoly on selling some drugs? The evidence indicates not. 
Firstly, community pharmacists may well act as a “screen,” effectively triaging people 
away from doctors’ surgeries by supplying these drugs, but doctors still have a high caseload 
of minor illness. In part, this is because recent reclassifications from prescription-only control 
to pharmacy medicines have all come with extra conditions to their sale, compared with when 
they are dispensed under prescription. (For example, UK pharmacists cannot give 1% 
hydrocortisone to children under 10, and “cautions in use” for triptans when prescribed by 
doctors became contraindications for retail sale.) This often results in consumers having to 
seek the drug through prescription from their doctor. 
Pharmacists have also questioned the value and use of some drugs that have been recently 
deregulated to “pharmacy medicines,”[7] and consumer demand for some of these drugs has 
been low: in the UK, for example, poor sales led to the withdrawal of simvastatin. 
Secondly, and more importantly, if pharmacy is to hold a monopoly on selling some 
medicines it needs to show value to consumers in terms of health outcomes, when compared 
with consumers purchasing these drugs without restriction. Evidence is lacking on this, but 
what is known is that community pharmacy practice has been criticised over its ability to sell 
pharmacy medicines appropriately all of the time.[8-10] More research is needed to establish 
whether and how pharmacists’ intervention affects patient outcomes. Furthermore, questions 
have been raised about pharmacists’ diagnostic ability, which tends to use rigid and 
established questioning strategies.[11][12] 
Time for a two tier system 
In the UK in the past four years just three drugs were switched from prescription-only 
control to pharmacy medicine status, but 12 pharmacy medicines were switched to general 
retail sale. The need for a “pharmacy medicines” category seems limited, especially as 
government policies seek to widen drugs’ availability. The decision to switch diclofenac back 
to prescription-only control will surely make manufacturers more cautious in seeking 
pharmacy medicine status for their prescription-only drugs, especially as the deregulatory 
process is lengthy, complex, and costly. 
In conclusion, without credible evidence to support the pharmacy medicines monopoly—
namely, that pharmacy intervention improves patient outcomes—it is only a matter of time 
before a two tier system of prescription or non-prescription drugs becomes the standard 
model, as in the US. 
This system is easy to understand: access to medicines is obtained either with a 
prescription or from any retail outlet. This is less confusing for consumers and increases 
accessibility, but it still allows pharmacies to sell drugs and gives them a chance to 
demonstrate their worth. 
Pull quote—Even with a system of restricted availability, doubt exists that pharmacists 
can supervise sales to consumers appropriately 
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